MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference
March 15, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R....
MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
February 28, 2022 16:06 ET
|
MiMedx Group, Inc
Fourth Quarter Net Sales of $67.4 Million and Full Year 2021 Net Sales of $258.6 Million; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products Vibrant Commercial...
Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care
February 16, 2022 08:35 ET
|
MiMedx Group, Inc
Use of MIMEDX PURION® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years MARIETTA, Ga., Feb. 16, 2022 (GLOBE...
MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28
February 14, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report...
MIMEDX Announces Dismissal of Putative Securities Class Action Lawsuit
January 28, 2022 12:40 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Jan. 28, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that a federal court...
MIMEDX Outlines Key Strategic Milestones for 2022
January 10, 2022 08:00 ET
|
MiMedx Group, Inc
MIMEDX Primed to Commence Pivotal Phase 3 Clinical Study Program of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) in Knee Osteoarthritis (KOA), Targeting Potential Late-2026 Commercial...
MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
January 04, 2022 16:05 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Jan. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R....
MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 22, 2021 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R....
MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
December 07, 2021 07:00 ET
|
MiMedx Group, Inc
Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022 Commercial Business Strategy...
MIMEDX Announces Speakers for December 7 Investor Day
November 30, 2021 08:00 ET
|
MiMedx Group, Inc
Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET MARIETTA, Ga., Nov. 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an...